#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1302	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2475	156.8	0	.	n	.	0	C451T	SNP	451	451	C	886	886	T	195	T	174	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1302	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2475	156.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1885	1885	T	177	T,G	160,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1302	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2475	156.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1619	1619	C	186	C	161	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2188	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3921	167.4	0	.	n	.	0	T695C	SNP	695	695	T	1211	1211	C	172	C,T	145,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2188	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3921	167.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2487	2487	C	218	C	193	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2188	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3921	167.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2561	2561	A	226	A	195	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2188	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3921	167.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3113	3113	C	213	C	178	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	178	folP	852	852	100.0	folP.l15.c4.ctg.1	1845	28.9	1	SNP	p	R228S	0	.	.	682	684	CGC	1181	1183	CGC	45;45;45	C;G;C	35;34;35	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	364	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3691	29.3	0	.	p	.	0	V19I	NONSYN	55	57	GTC	500	502	ATC	34;34;34	A;T;C	29;28;29	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	364	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3691	29.3	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1193	1195	ATA	28;28;28	A;T;A	23;24;25	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	364	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3691	29.3	1	SNP	p	S91F	0	.	.	271	273	TCC	716	718	TCC	29;29;30	T;C;C	26;26;27	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	364	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3691	29.3	1	SNP	p	D95G	0	.	.	283	285	GAC	728	730	GAC	29;28;28	G;A;C	27;25;26	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	364	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3691	29.3	1	SNP	p	D95N	0	.	.	283	285	GAC	728	730	GAC	29;28;28	G;A;C	27;25;26	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	178	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1663	32.2	0	.	p	.	0	D79N	NONSYN	235	237	GAT	762	764	AAT	49;49;49	A;A;T	43;43;44	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	178	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1663	32.2	1	SNP	p	G45D	0	.	.	133	135	GGC	660	662	GGC	43;43;42	G;G;C	36;36;36	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	120	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1293	27.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1679	1681	ATC	53;53;54	A;T;C	47;46;46	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1790	1792	GCC	54;54;54	G;C,T;C	46;45,1;44	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1832	1834	GCA	53;53;53	G;C;A	46;46;47	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	0	.	p	.	0	I596V	NONSYN	1786	1788	ATT	2315	2317	GTT	52;52;52	G;T;T	47;44;47	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	1	SNP	p	D86N	0	.	.	256	258	GAC	785	787	GAC	40;40;40	G;A;C	36;36;36	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	1	SNP	p	S87R	0	.	.	259	261	AGT	788	790	AGT	40;40;40	A;G;T	35;35;36	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	1	SNP	p	S87W	0	.	.	259	261	AGT	788	790	AGT	40;40;40	A;G;T	35;35;36	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	1	SNP	p	S87I	0	.	.	259	261	AGT	788	790	AGT	40;40;40	A;G;T	35;35;36	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	390	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3327	35.2	1	SNP	p	S88P	0	.	.	262	264	TCC	791	793	TCC	40;40;40	T;C;C	35;34;36	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	310	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2977	31.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1766	1768	GGC	40;40;40	G;G;C	36;37;37	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1415	1417	GCA	53;51;51	G;C;A	43;40;40	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1418	1420	ATC	51;51;51	A;T;C	42;42;42	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1430	1432	GTG	48;48;48	G;T;G	39;40;40	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1430	1432	GTG	48;48;48	G;T;G	39;40;40	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1931	1933	ACC	41;42;42	A;C;C	34;37;38	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1985	1987	GCG	42;42;43	G;C;G	36;33;34	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1985	1987	GCG	42;42;43	G;C;G	36;33;34	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2108	2110	GGC	49;48;48	G;G;C	34;37;39	penA.0.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2117	2119	GGC	50;49;49	G;G;C	35;37;36	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	352	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2728	38.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2135	2137	CCG	49;49;49	C;C,A;G	34;40,1;37	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	283	504	ponA	2397	2397	99.87	ponA.l6.c30.ctg.1	3698	40.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	174	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2188	23.7	0	.	p	.	0	S22G	NONSYN	64	66	AGC	591	593	GGT	31;31;31	G;G;T	26;25;26	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	174	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2188	23.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	773	773	C	35	C	31	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	A29V	NONSYN	85	87	GCC	578	580	GTC	47;47;48	G;T,C;C	39;38,1;39	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	T50A	NONSYN	148	150	ACT	641	643	GCT	48;48;49	G;C,G;T,C	42;40,1;42,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	K88L	NONSYN	262	264	AAA	755	757	CTC	57;58;59	C;T;C	47;46;47	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	S93N	NONSYN	277	279	AGC	770	772	AAC	56;56;57	A;A;C	48;49;49	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	H111R	NONSYN	331	333	CAT	824	826	CGT	57;57;57	C;G;T,G	51;50;51,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	N114S	NONSYN	340	342	AAC	833	835	AGC	58;58;58	A;G;C	51;49;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	I115V	NONSYN	343	345	ATC	836	838	GTC	59;59;59	G;T;C	52;50;49	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	D120G	NONSYN	358	360	GAC	851	853	GGC	58;59;59	G;G;C	52;52;53	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	R143H	NONSYN	427	429	CGC	920	922	CAC	68;68;68	C;A;C	58;58;58	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	1094	1096	TTC	71;71;71	T;T;C	58;60;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	T202M	NONSYN	604	606	ACG	1097	1099	ATG	73;73;75	A;T;G	60;63;64	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	290	porB1a	984	984	98.27	porB1a.l15.c4.ctg.1	1822	47.3	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1199	1201	CGC	67;67;69	C;G;C	62;64;64	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	910	rpoB	4179	4179	99.93	rpoB.l15.c4.ctg.1	5189	52.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2180	2182	CAT	52;52;52	C;A;T	42;42;43	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	178	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1222	43.7	1	SNP	p	V57M	0	.	.	169	171	GTG	626	628	GTG	75;75;75	G;T;G	65;66;62	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
